Ambu A/S Class B
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Britt Meelby Jensen
- Full Time Employees
- 5,384
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Baltorpbakken 13 Ballerup CR Denmark 2750
- IPO Date
- Mar 9, 1992
- Website
- ambu.com
- Similar Companies
- Business
- Ambu A/S (Ticker: AMBU-B.CO) develops, manufactures, and markets single-use flexible endoscopic devices and related visualization systems for medical diagnostics and treatment procedures. The company offers a comprehensive portfolio of products including flexible endoscopes such as the aScope line of bronchoscopes, duodenoscopes, cystoscopes, and ureteroscopes; disposable sheaths and cleaning brushes; and advanced imaging solutions like the aView and aBox systems for video processing and display. Ambu also provides rigid endoscopy products, patient monitoring devices, and resuscitators, serving healthcare providers in hospitals, clinics, and ambulatory settings worldwide. Founded in 1937 and headquartered in Ballerup, Denmark, Ambu operates globally with manufacturing facilities in Europe, North America, and Asia, targeting key markets in endoscopy, anesthesia, and cardiology segments. Its core customer base includes physicians, nurses, and medical facilities focused on minimally invasive procedures, with a strong emphasis on infection prevention through single-use devices. The company maintains subsidiaries in major regions, including Ambu Inc. in the United States, supporting its international expansion. In the last 1-2 years, Ambu has launched several new products, including the aScope™ 5 Slim Broncho and advancements in its aScope™ Gastro platform for gastrointestinal endoscopy, enhancing procedural efficiency and safety. The company completed strategic acquisitions such as the 2024 purchase of a key visualization technology firm to bolster its digital endoscopy offerings and formed partnerships with leading hospital networks for pilot programs in single-use endoscopy adoption. Additionally, Ambu announced expansions in its U.S. manufacturing capacity in 2025 to meet growing demand in North American markets amid regulatory shifts favoring disposable devices.
Company News
NovoCure (NASDAQ:NVCR) and Ambu A/S (OTCMKTS:AMBBY) Head to Head Contrast
Reviewing ICU Medical (NASDAQ:ICUI) & Ambu A/S (OTCMKTS:AMBBY)
Ambu A/S (AMBBY) Q3 2026 Earnings Call Transcript
Ambu A/S (OTCMKTS:AMBBY) Sees Large Volume Increase – What’s Next?
Ambu A/S (AMBBY) Q1 2026 Earnings Call Transcript
Ambu A/S (AMBBY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Ambu A/S (OTCMKTS:AMBBY) Trading 3.4% Higher – Still a Buy?
Ambu A/S (AMBBY) Shareholder/Analyst Call Prepared Remarks Transcript
Ambu A/S (AMBBY) Q4 2025 Earnings Call Transcript
Ambu upgraded to Buy from Hold at Nordea
Ambu A/S (AMBFF) Q4 2024 Earnings Call Transcript
Ambu A/S (AMBFF) Q1 2024 Earnings Call Transcript
Ambu A/S (AMBFF) Q2 2023 Earnings Call Transcript
Ambu A/S (AMBFF) Q4 2022 Earnings Call Transcript